Navitor Pharmaceuticals Secures $33,000,000 Series B Financing

  • Feed Type
  • Date
    12/18/2015
  • Company Name
    Navitor Pharmaceuticals
  • Mailing Address
    1030 Massachusetts Avenue Cambridge, MA 02138 USA
  • Company Description
    New scientific insights are emerging regarding the primal signaling pathways that direct an organism’s metabolic response to conditions in its environment—such as dynamic changes in the availability of nutrients, energy, oxygen and other factors—and the role of these metabolic signaling pathways in disease.
  • Website
    http://www.navitorpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $33,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The Series B funding will enable Navitor to advance a lead program into clinical trials with the objective of demonstrating initial efficacy and safety. The company will also continue to develop additional pipeline candidates and augment its proprietary drug discovery platform.
  • M&A Terms
  • Venture Investor
    Brace Pharma
  • Venture Investor
    Remeditex Ventures
  • Venture Investor
    Sanofi-Genzyme BioVentures
  • Venture Investor
    Polaris Partners
  • Venture Investor
    Accomplice
  • Venture Investor
    SR One
  • Venture Investor
    Johnson & Johnson Development Corporation